Last reviewed · How we verify
NCT04282096
Nutritional Caracterisation of Micellar Casein
NA trial testing native and non native casein in Protein Digestion in 12 participants. Completed in 5 November 2018.
30 October 2018
Quick facts
| Lead sponsor | Ingredia S.A. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 12 |
| Start date | 23 August 2018 |
| Primary completion | 30 October 2018 |
| Estimated completion | 5 November 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- native and non native casein
Conditions studied
- Protein Digestion — all drugs for Protein Digestion →
Sponsor
Ingredia S.A.
Who can join
Adults 20 to 40, male only, with Protein Digestion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There are different types of casein on the market, which differ according to their chemical or physical process of obtaining. The processes will impact structural differences in the macromolecular assembly. The majority of caseins marketed in nutrition are casein in the form of Na caseinate or Ca caseinate. The micellar caseins obtained by membrane filtration (physical process) are more and more used in the nutrition market. The development of casein extraction with different structures on an industrial scale opens up other perspectives for these proteins, particularly in terms of health. The main objective of this project is to study the postprandial kinetics of the plasma concentrations of the essential amino acids of three structurally different types of caseins. The secondary objective is to study the speed of gastric emptying and the nutritional properties of different proteins.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04282096
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ingredia S.A. trials
Trials by the same sponsor.
- NCT06378034 — Effect of Lactium on Sleep Disorders in Healthy Volunteers With Persistent Subclinical Insomnia · NA · not yet recruiting
- NCT05391854 — Clinical Study to Assess the Long-term Effect of Pep2Dia® on Glucose Homeostasis in Prediabetic Subjects · NA · completed
- NCT04375449 — Investigation of Milk Peptides (Pep2Dia®) on Postprandial Blood Glucose Profile in Prediabetic Subjects · NA · completed
- NCT03932695 — Investigation of Milk Peptides on Postprandial Blood Glucose Profile · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04282096 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ingredia S.A.
- Last refreshed: 24 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04282096.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing